Methods: Two protocols (ie, preventive and therapeutic protocol) were designed to evaluate the effects of LTS61K in Der p sensitized and challenged mouse model of asthma. Results: Both intranasal inoculations with LTS61K or LTS61K/Der p decreased allergen-induced airway inflammation and alleviated systemic T H 2-type immune response. In addition, bronchoalveolar lavage (BAL) fluids and sera from LTS61K/Der p treated mice have higher concentrations of Der p-specific IgA than those of other groups. In the in vitro study, bone marrowderived dendritic cells (BMDCs) and DC cell line, DC2.4 cells stimulated with LTS61K/Der p both secreted pro-inflammation cytokines IL-6 and TNFa. In contrast, after LTS61K treatment, only BMDCs decreased production of IL-6 and TNF-a as well as decreased maturation. Furthermore, we found that pre-treatment BMDC with LTS61K inhibited Der p-induced NF-kB translocation which might explain the delayed maturation and decreased productions of IL-6 and TNF-a in LTS61K pre-treated BMDCs. Intratracheally adoptive transferred with LTS61K-or LTS61K/Der p-primed DC2.4 cells or BMDCS into Der p-sensitized mice decreased inflammatory cells infiltration and T H 2-type chemokines in BAL fluids and alleviated airway inflammation. Conclusions: Our results show that LTS61K may influence DCs maturation and its cytokine production. On the other hands, LTS61K/Der p may induce more Der p-specific IgA production to decrease allergic T H 2 cytokine responses and alleviate airway inflammation in murine model of asthma. These finding suggested that LTS61K may have clinical application as an immune-modulator effect on the diseases of allergy and asthma. Center for Rhinology and Allergology, Department of Otorhinolaryngology, University Hospital Mannheim, Wiesbaden, Germany. Background: The safety and efficacy of specific immunotherapy (SIT) with depigmented and polymerized allergen extracts of pollen is well documented in several clinical trials. We investigated efficacy and safety of an extract containing 2 taxonomically non-related pollen species (birch and grasses) in a subcutaneous immunotherapy over 2 pollen seasons in co-sensitized allergic patients with rhinitis and/or rhinoconjunctivitis with or without allergic asthma. Methods: 269 (ITT) patients with confirmed rhinitis and/or rhinoconjunctivitis were treated during 2009 and 2010 in Germany, Romania, Poland, Lithuania, and Bulgaria. For each patient a 1-day build-up phase applying 0.2 mL and 0.3 mL of 1000 DPP/mL allergen extract was applied. During the remaining 18-month period maintenance 500 DPP were administered in 4 to 6 weeks intervals. Patients were randomised to the treatment groups on a 2:1 basis (175 verum: 94 placebo). The main parameter in this study was the combined symptom and medication score during the birch and grass pollen season 2010 over 7 weeks. Secondary parameters were symptom score, medication score, IgE, IgG4 as well as quality of life. Results: During the 2010 season a statistically significant difference (P ¼ 0.0385) was observed between treatment groups: in patients treated with the allergen extract the median time weighted AUC of the combined symptom and medication score was 5.70, in patients treated with placebo 7.07. This effect was predominantly due to the reduction of symptom score by 21% over placebo. The intake of recue medication was very low during both seasons leading only to a 10% reduction (ns). Birch and phleum specific IgE did not change during the course of the study in both groups whereas respective IgG4 levels increased only in the verum group and remained nearly unchanged in the placebo group (P , 0.0001). Total QoL score was improved in verum patients (P ¼ 0.0254). 5.4% of the patients in the verum group and 4.0% of the patients in the placebo group developed mild systemic reactions.
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Conclusions:
The results show that specific immunotherapy with a depigmented polymerized extract of 2 taxonomically non-related pollen (birch and grass) was effective and safe demonstrated by clinical and immunological parameter. Background: Allergoids have been successfully used in the treatment of respiratory allergic diseases. They are modified allergen extracts that allow the administration of high allergen doses, due to their reduced IgE binding capacity.They maintain allergen-specific T-cell recognition. Since they are native allergen extracts that have been polymerized with glutaraldehyde, identification of the allergenic molecules requires more complicated methods. The aim of the study was to determine the qualitative composition of different polymerized extracts and investigate the presence of defined allergenic molecules using Mass spectrometry. Methods: Proteomic analysis was carried out at the Proteomics Facility of the Hospital Nacional de Parapléjicos (Toledo, Spain). After reduction and alkylation, proteins were digested with trypsin and the resulting peptides were cleaned using C18 SpinTips Sample Prep Kit; peptides were separated on an Ultimate nano-LC system using a Monolithic C18 column in combination with a precolumn for salt removal. Fractionation of the peptides was performed with a Probot microfraction collector and MS and MS/MS analysis of offline spotted peptide samples were performed using the Applied Biosystems 4800 plus MALDI TOF/TOF Analyzer mass spectrometer. ProteinPilot Software V 2.0.1 and the Paragon algorithm were used for the identification of the proteins. Each MS/MS spectrum was searched against the SwissProt 2010_10 database, Uniprot-Viridiplantae database and Uniprot_Betula database. Results: Analysis of the peptides revealed the presence of native allergens in the polymerized extracts: Der p 1, Der p 2, Der p 3, Der p 8 and Der p 11 in D. pteronyssinus; Bet v 2, Bet v 6, Bet v 7 and several Bet v 1 isoforms in B. verrucosa and Phl p 1, Phl p 3, Phl p 5, Phl p 11 and Phl p 12 in P. pratense allergoids. In all cases, potential allergenic proteins were also identified, including ubiquitin, actin, Eenolase, fructose-bisphosphate aldolase, luminalbinding protein (Heat shock protein 70), calmodulin, among others. Conclusions: The characterization of the allergenic composition of allergoids is possible using MS/MS analysis. The analysis confirms the presence of native allergens in the allergoids. Mayor allergens are preserved during polymerization.
